Search Results (14,239)

Background/Objectives: The skin microbiome maintains barrier integrity, immune homeostasis, and pathogen defense; dysbiosis contributes to acne vulgaris, dandruff, seborrheic dermatitis, atopic dermatitis, psoriasis, and alopecia. This scoping review critically appraised evidence on prebiotics, probiotics, synbiotics, postbiotics, and paraprobiotics in dermo-cosmetics for acne vulgaris and scalp disorders. Methods: A scoping search (2006–2026) covered SciELO, PubMed/PMC, Google Scholar, CAPES Portal, Scopus, Heliyon, Frontiers, Nature, Wiley, and MDPI, following PRISMA 2020 guidelines. Results: Of 1665 records, 66 were included. For acne, effective prebiotics included blackcurrant, grape seed, ginseng, trehalose, and glucomannan hydrolysate; effective probiotic strains included Streptococcus thermophilus, Bifidobacterium longum, Staphylococcus epidermidis, and Streptococcus salivarius. A synbiotic (B. breve BR03, Lacticaseibacillus casei LC03, Ligilactobacillus salivarius LS03) reduced inflammatory lesions by 56.67% in an 8-week RCT (n = 114). For scalp disorders, oral Lacticaseibacillus paracasei ST11 reduced dandruff by 70% vs. 23% (placebo); Lactiplantibacillus plantarum TCI999 increased hair root diameter (n = 50, 12 weeks); a Lacticaseibacillus rhamnosus plus Bifidobacterium longum mixture improved alopecia areata by 56% vs. 30% (n = 26, 24 weeks). Conclusions: Biotic dermo-cosmetics can modulate the cutaneous microbiome and attenuate inflammation in acne and scalp disorders, with strongest evidence for multi-strain/synbiotic formulations. Formulation stability, strain specificity, regulatory heterogeneity, and lack of standardized microbiological endpoints remain key challenges; larger standardized RCTs with active comparators are needed. Full article

Alcohol consumption has been increasingly associated with alterations in the gut microbiota and its metabolic activity; however, evidence regarding microbiota-derived metabolites remains fragmented. This systematic review aimed to synthesize current evidence on the effects of alcohol consumption on gut microbiota-derived metabolites in humans and non-human primates. The review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included studies published between 2012 and 2026. Searches were performed in PubMed, Web of Science, Scopus, and ScienceDirect. Study quality was assessed using the Newcastle–Ottawa Scale for human studies and the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) Risk of Bias tool for non-human primate studies. Twelve studies met the inclusion criteria, comprising four non-human primate studies and eight human studies. Alcohol exposure was consistently associated with metabolomic alterations across multiple biological matrices. Recurrent findings included reductions in short-chain fatty acids, alterations in tryptophan-derived metabolites, changes in phenolic and aromatic amino acid-related compounds such as hippuric acid, and disturbances in bile acid and purine metabolism. Findings regarding microbial diversity and taxonomic composition were more heterogeneous, with several studies reporting reduced abundances of Faecalibacterium and related butyrate-producing taxa. Studies evaluating abstinence suggested partial recovery of both microbial and metabolomic alterations. Overall, the available evidence suggests that alcohol consumption is associated with alterations across several microbiota-related metabolic pathways, highlighting candidate metabolites that may contribute to alcohol-related pathophysiology and serve as potential translational biomarkers. Full article

Agro-industrial by-products are increasingly considered as feed resources for circular animal production, but their value should not be interpreted only as a low-cost replacement of conventional ingredients. This scoping review critically examines how by-products from grape, olive, tomato, citrus, cereal, brewery, oilseed and vegetable processing chains may contribute to the development of high-value animal-derived foods. Particular attention is given to bioactive compounds, polyphenols, carotenoids, tocopherols, fermentable fibres and residual lipids, as well as to microbiome-mediated biotransformation, host metabolic pathways, compound transfer, product-quality modulation, feed safety and circular valorization. Available evidence indicates that selected by-products can influence milk, cheese, meat, eggs and fish products by modifying fatty acid profile, oxidative stability, antioxidant-related traits, pigmentation, volatile compounds, shelf-life and, in some cases, the transfer of specific metabolites to edible products. However, these responses depend on by-product source, processing method, inclusion level, active dose, animal species, basal diet and analytical endpoints. Chemical richness alone is therefore insufficient to support functional claims. Stronger evidence requires studies that connect matrix characterization, processing stability, microbial and host-mediated transformation, biological intermediates and final product quality within the same experimental design. Precision circular feeding should therefore combine local availability, safety, active-dose definition, metabolomic and lipidomic traceability, and product-level validation to support reproducible improvements in high-value animal-derived foods. Full article

Short stature is a common pediatric endocrine–metabolic disorder characterized by impaired linear growth and increased risks of adverse health outcomes. Although previous reviews have summarized associations between gut microbiota and childhood health, few have focused on the mechanistic links among microbial composition, microbial-derived metabolites, endocrine regulation, and skeletal growth in short stature. This review provides an integrated framework exploring the potential interactions among gut microbiota composition, microbial-derived metabolites, endocrine regulation, and skeletal development in short stature. We summarize the clinical characteristics and epidemiological features of major short stature subtypes and discuss emerging evidence demonstrating the involvement of gut microbiota alterations and metabolite dysregulation in growth regulation. Particular attention is given to the bidirectional interactions between the gut microbiota and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, as well as the potential role of the gut–liver–bone axis in skeletal growth. Furthermore, this review integrates evidence from metabolomics studies, experimental animal models, and microbiota-targeted interventions to provide mechanistic insights into microbiota-mediated growth regulation. Dietary factors, physical activity, sleep, antibiotic exposure, probiotic interventions, and current clinical treatments are also discussed from the perspective of microbiota modulation. Despite increasing interest in microbiota-based strategies, clinical translation remains limited by insufficient functional validation, unclear causal relationships, and a lack of well-designed intervention trials. Future integration of functional microbiology, multi-omics approaches, and human-based validation platforms may facilitate the development of microbiome-based precision interventions for improving growth outcomes in children with short stature, particularly those with ISS. Full article

Abiotic stresses increasingly threaten crop productivity, whereas reliance on chemical and resource-intensive interventions can compromise environmental sustainability. Existing literature identifies Trichoderma spp. as multifunctional biocontrol agents, biofertilizers, and microbial biostimulants capable of influencing plant growth, stress signaling, and rhizosphere processes; however, evidence remains fragmented across strains, crops, formulations, and stress conditions. This review aimed to integrate current knowledge on Trichoderma-mediated resilience to salinity, drought, heavy metals, temperature extremes, and emerging pollutants, while distinguishing experimentally validated mechanisms from statistical associations and conceptual inference. It evaluates constraints governing reproducibility from controlled studies to field deployment. The synthesis shows that selected crop–strain systems improve root architecture, photosynthesis, antioxidant regulation, osmotic adjustment, nutrient acquisition, ion homeostasis, hormonal balance, and stress-responsive gene expression. Benefits arise through coordinated delivery, root colonization, metabolite and protein signaling, physiological reprogramming, and rhizosphere modulation. Nevertheless, microbiome co-occurrence patterns do not establish causal network repair, evidence for broad heat and cold protection remains limited, and biochar co-application should not be interpreted as a carrier formulation without direct validation. Future progress requires strain- and crop-specific screening, mechanistic gene and protein studies, standardized formulations, combined-stress experiments, multi-location field trials, biosafety evaluation, and farmer-level economic assessment to develop reliable precision microbial technologies. Full article

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that arises from a complex interplay of genetic susceptibility, immune dysregulation, environmental exposures, and altered host–microbiome interactions. Increasing evidence identifies the gut microbiota as a central component of IBD pathogenesis. In healthy individuals, the intestinal microbiota supports epithelial integrity, metabolic homeostasis, immune education, colonization resistance, and bidirectional gut–brain communication. In IBD, this ecosystem is disrupted by reduced microbial diversity, expansion of pathobionts, and broader functional alterations affecting community stability and metabolic output. Importantly, these changes are increasingly viewed not merely as consequences of inflammation, but as active contributors to disease development and persistence. Dysbiosis may also influence neuroimmune signaling through the gut–brain axis, linking microbial metabolites, intestinal barrier dysfunction, enteric nervous system activity, and psychological comorbidities frequently observed in patients with IBD. This review provides a comprehensive overview of the role of the gut microbiota in IBD, beginning with its physiological functions in intestinal homeostasis and the evidence linking dysbiosis to disease pathogenesis, followed by a critical evaluation of current microbiome-based therapeutic strategies, their translational challenges, and prospects for personalized microbiota-directed interventions. Approaches such as fecal microbiota transplantation (FMT), probiotics, live biotherapeutic products, and genetically engineered bacteria aim to restore microbial balance and modulate intestinal inflammation. Among these, FMT has provided the strongest proof-of-concept for microbiome restoration, whereas probiotic efficacy remains variable and strain-dependent. Emerging defined microbial consortia and engineered bacterial platforms offer improved standardization and mechanistic precision, but their clinical application remains limited by challenges related to engraftment, durability of response, safety, and treatment optimization. Collectively, current evidence supports gut microbiota as both a key determinant of IBD pathogenesis and a promising therapeutic target, underscoring the need for more precise and personalized microbiota-directed approaches in IBD management. Full article

Background: Dental caries is a highly prevalent, biofilm-mediated disease characterized by microbial dysbiosis, excessive acid production, and progressive enamel demineralization. Although traditionally managed through restorative treatment, increasing attention has shifted toward preventive strategies focused on modulation of the oral microbiota and maintenance of ecological balance within the oral cavity. Methods: This narrative review summarizes current evidence regarding the ecological and mechanistic basis of dental caries and microbiota-centered prevention strategies. Literature published between January 2000 and March 2026 was retrieved from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar using keywords related to dental caries, oral microbiota, cariogenic bacteria, biofilms, probiotics, prebiotics, salivary diagnostics, metabolomics, quorum sensing, and artificial intelligence. Results: Current evidence demonstrates that dental caries is driven by ecological shifts favoring acidogenic and aciduric microorganisms within cariogenic biofilms. Emerging preventive approaches include dietary modification, oral hygiene optimization, probiotics, prebiotics, synbiotics, and functional dietary agents aimed at restoring microbial homeostasis and inhibiting cariogenic biofilm maturation. In addition, advances in salivary microbiome profiling, metabolomics, artificial intelligence-assisted predictive modeling, and smart responsive materials have shown promising potential for improving early diagnosis, risk assessment, and personalized prevention strategies. Conclusions: Microbiota-based approaches represent a promising paradigm shift in dental caries prevention by emphasizing ecological modulation rather than pathogen eradication alone. Continued interdisciplinary research integrating microbial ecology, diagnostics, biomaterials, and digital technologies may facilitate the development of personalized and preventive oral healthcare strategies. Full article

Food additives are consumed as mixtures in ultra-processed foods, but their independent contribution to glucose dysregulation is difficult to separate from diet quality and food matrix. PubMed/MEDLINE, Embase, Web of Science Core Collection, Scopus, and CENTRAL were searched from inception to 30 April 2026, followed by a supplementary PubMed update on 26 July 2026. This critical narrative review integrates epidemiological, human-intervention, animal, ex vivo, and mechanistic evidence. Successive NutriNet-Santé analyses associate several additive co-exposure profiles, emulsifiers, preservatives, food colouring additives, and non-nutritive sweeteners with incident type 2 diabetes mellitus. However, these analyses use substantially overlapping participants, lack independent additive-specific cohort replication, and remain vulnerable to residual confounding. Experimental evidence is strongest for selected emulsifiers and sweeteners, which may alter gut microbiota, intestinal barrier function, inflammatory signalling, or short-term glycaemic responses. No human trial has demonstrated the complete pathway from additive exposure to clinically meaningful insulin resistance or diabetes, and null or compound-specific findings argue against a uniform class effect. Current evidence therefore supports biological plausibility, not causality or additive-specific clinical recommendations. Longer controlled feeding trials should test realistic mixtures while holding the food matrix constant and should incorporate exposure validation, repeated microbiome and metabolomic sampling, intestinal permeability measures, and validated insulin-sensitivity endpoints. Full article

Background: Recurrent implantation failure (RIF) remains one of the most challenging conditions in reproductive medicine. Although increasing evidence implicates chronic endometritis (CE) and alterations of the endometrial microbiota in impaired implantation, the potential contribution of gastrointestinal dysfunction and intestinal dysbiosis remains poorly characterized. We hypothesized that, in a subgroup of women with pure RIF, reproductive failure may be associated with a broader mucosal phenotype involving both intestinal and endometrial compartments. Objective: To characterize the coexistence of gastrointestinal disorders, intestinal dysbiosis, CE, and endometrial microbial alterations in women diagnosed with pure RIF, and to descriptively report reproductive outcomes observed during subsequent multidisciplinary clinical management. Methods: This retrospective, single-centre, observational, hypothesis-generating study included women who met the strict ESHRE criteria for pure RIF, and were assessed at the “Federico II” IVF Centre, Naples, Italy. Patients underwent multidisciplinary assessment combining reproductive medicine, outpatient hysteroscopy, gastroenterological evaluation according to Rome IV criteria, conventional microbiological investigation and paired intestinal and endometrial microbiome characterization by 16S rRNA sequencing. Following clinical assessment, individualized gastroenterological management was undertaken according to routine practice. Reproductive outcomes were descriptively recorded during follow-up. Results: 19 women were analysed, all of whom met the Rome IV guidelines, and showed hysteroscopic and histologic signs of CE. Gut dysbiosis was identified in 94.7% (18/19) of patients, whereas endometrial microbial alterations were observed in 78.9% (15/19). In 84.2% (16/19) of the cohort, microbial profiles characterized by an abundance of Enterobacteriaceae in the intestinal and/or endometrial compartments were detected. Conventional microbiological positivity was present in less than half of patients, highlighting the distinction between microbiological infection and ecological microbial imbalance. During the follow-up period following completion of the personalized multidisciplinary treatment program, which included the administration of a well-characterized probiotic strain, Escherichia coli Nissle 1917, 11 women (57.9%) achieved a clinical pregnancy. Dysbiosis of the intestine was reported in 94.7% (18 out of 19) of participants, whereas endometrial microbiota disturbances were present in 78.9% (15 out of 19) of subjects. The Enterobacteriaceae-enriched microbiota profiles affecting the intestine and/or endometrium were seen in 84.2% (16 out of 19) of subjects. Out of 19 patients, 11 (57.9%) conceived during the follow-up period after gut-targeted treatment comprising Escherichia coli Nissle 1917. Conclusions: Women who meet strict criteria for pure RIF may represent a clinically identifiable subgroup characterized by the coexistence of gastrointestinal disorders, intestinal dysbiosis, CE, and endometrial microbial alterations. Rather than demonstrating therapeutic efficacy, the present study provides a translational and hypothesis-generating framework supporting the need for prospective validation of this integrated biological phenotype in women with pure RIF before evaluating personalized multidisciplinary management. Prospective controlled studies are warranted to evaluate whether gut-directed interventions may influence reproductive outcomes in this population. Full article

The gut microbiota and its metabolic functions are critical for intestinal homeostasis, but their integrated responses to diarrhea remain poorly understood in non-model mammals, such as the complex-toothed flying squirrel (Trogopterus xanthipes). Here, we collected fecal samples from six captive animals with diarrhea and six healthy controls; the diarrheal animals had been provided with moldy corn, but mycotoxin levels were not measured. Fecal microbiota was profiled by full-length 16S rRNA sequencing and untargeted metabolomics with integrative analyses. Diarrheal animals showed significantly decreased fecal microbial alpha-diversity and distinct community separation. LEfSe analysis identified Lawsonia intracellularis and Streptococcus macedonicus as the most enriched taxa in the diarrhea group. Untargeted metabolomics revealed 2216 differential metabolites (1931 downregulated), primarily enriched in steroid hormone biosynthesis, arachidonic acid metabolism, and bile secretion pathways. Procrustes and Mantel tests confirmed significant microbiome–metabolome concordance (M² = 0.422, p < 0.001). Spearman correlation networks showed that L. intracellularis was positively correlated with multiple differential metabolites, while S. macedonicus exhibited predominantly negative correlations. These findings suggest that diarrhea in T. xanthipes may be associated with moldy corn exposure and is accompanied by gut dysbiosis and metabolic disturbances. L. intracellularis and S. macedonicus may be associated with disease progression through pathways linked to lipid and bile acid metabolism and inflammation. This study provides novel microbial–metabolic insights into diarrhea in a medicinal mammal, supporting disease prevention and healthy breeding. Full article

The use of invertebrates for sewage sludge bioconversion offers a sustainable strategy for waste valorization, yet species-specific effects on microbial communities and biosafety remain unclear. Here, we compared the impacts of the earthworm Eisenia andrei (Ea) and the mealworm Tenebrio molitor (Tm) on the bacteriomes and mycobiomes of sewage sludge (ss) using 16S rRNA and ITS amplicon sequencing. Gut passage in both Ea and Tm markedly altered bacterial and fungal composition relative to ss, but produced distinct community profiles with differential shifts across multiple taxa. Both invertebrates reduced bacterial richness by ~40%, while fungal responses diverged: Ea largely preserved mycobiome richness despite reduced evenness, whereas Tm caused a near-complete collapse (~83% Amplicon Sequence Variant loss). Beta diversity analyses revealed clear, non-overlapping separation among ss, Ea, and Tm for both microbial domains. Tm frass showed strong enrichment of clinically relevant bacterial pathogens, while Ea casts exhibited no such enrichment. For fungi, Ea reshaped pathogen composition, whereas Tm largely eliminated fungal pathogens through broad community collapse. Both treatments reduced predicted antibiotic resistance gene abundance, but functional profiles differed, with Ea showing greater functional stability. These findings demonstrate that microbiome restructuring during bioconversion is species-dependent, with contrasting ecological and biosafety implications for downstream environmental use. Full article

Dysbiosis-related oral biofilm diseases, particularly dental caries and periodontal diseases, pose major global health challenges because ecological shifts within oral microbial communities enhance biofilm virulence, resilience, and host inflammatory responses. Cannabidiol (CBD), a non-psychoactive phytocannabinoid with antimicrobial, antibiofilm, immunomodulatory, and antioxidant properties, has attracted increasing interest as an investigational, ecology-oriented adjunct for oral health applications. This narrative review evaluates current antibiofilm, antivirulence, and host response evidence for CBD in dysbiosis-related oral biofilm diseases, with emphasis on dental caries and periodontal diseases and selected supportive evidence from other oral biofilm-associated conditions. Current evidence suggests that CBD can inhibit biofilm formation, attenuate cariogenic and fungal virulence traits, modulate periodontal inflammation and immunity, and support tissue-protective responses. However, most evidence remains preclinical and model-dependent, particularly in caries research, and CBD’s hydrophobicity, limited stability, uncertain dose windows, and incomplete microbiome-level evidence remain major barriers to translation. Future studies should clarify CBD’s ecological effects on oral microbial communities, define clinically relevant dosing and exposure timing, and develop oral-retentive delivery systems. Full article

Background: Metronomic chemotherapy (MCT), understood as continuous, low-dose cytotoxic administration without prolonged drug-free intervals, has become an established strategy in several solid tumors, acting primarily through antiangiogenic, immunomodulatory, and direct cytostatic mechanisms rather than replication-dependent cytotoxicity. Despite an expanding evidence base, including positive randomized trials, validated predictive biomarkers of response remain unavailable. Methods: We searched PubMed/MEDLINE, Embase, and ClinicalTrials.gov (January 2000 to July 2026) for phase II/III randomized trials, prospective cohorts, and selected retrospective analyses of MCT in breast cancer, head and neck squamous cell carcinoma, NSCLC, and mCRC, and extracted biomarker data from embedded translational substudies of eligible trials. Results: In breast cancer, phase III SYSUCC-001 (adjuvant metronomic capecitabine, improved DFS in TNBC) and MECCA (metronomic capecitabine plus aromatase inhibitor in HR+/HER2− disease) provide the strongest evidence, supported by randomized phase II data for the VEX regimen (METEORA-II) and MCT-anti-PD-1 combinations. TEMPO LUNG established metronomic vinorelbine as effective in platinum-unfit NSCLC, while CAIRO3 confirmed metronomic capecitabine–bevacizumab as an effective mCRC maintenance therapy. Most recently, the phase III TMC-I trial extended positive randomized evidence to head and neck cancer. Candidate biomarkers span angiogenic, immune, tumor proliferative, molecular, pharmacodynamic cytokine, on-treatment clinical (adverse-event-based), and gut–microbiome domains, with FOXC1, circulating endothelial cell kinetics, VEGF pathway markers, and regulatory T-cell dynamics among the most promising; however, none has been prospectively validated in a dedicated confirmatory trial. Conclusions: MCT has moved from empirical use to an evidence-based strategy across multiple tumor types, but the lack of validated predictive biomarkers limits informed patient selection. Future trials should incorporate biomarker-driven designs, particularly FOXC1, endothelial cell kinetics, and immune profiling as co-primary objectives. Defining an MCT-sensitive biological phenotype remains the key translational challenge for the field. Full article

Precision health is often presented as the expansion of measurement, prediction and personalization: more biomarkers, more omics layers, more digital traces and more artificial intelligence. Yet data density does not by itself produce orientation, responsibility or better care. This Perspective introduces the Allostatic Viability Principle (AVP) as a systems framework for responsible precision health. Drawing on the biological logic of allostasis and the systems concept of viability, the AVP argues that health systems remain responsible not by freezing static parameters, but by preserving their capacity for regulated openness, feedback-sensitive adjustment and accountable correction. The framework is operationalized through four interdependent system functions: boundary, exchange, feedback and correctability. It further distinguishes population-based biomarker norms from individual trajectories and patient-defined health objectives. The biological analogy is used as a conceptual lens: it does not provide a blueprint for institutional design, but helps to identify when precision health systems remain responsive, and when they become closed, noisy or uncorrectable. The Perspective integrates systems theory, epigenetic and microbiome regulation, precision nutrition, allostatic load, salutogenesis, evolutionary developmental biology, digital health and AI governance. The paper argues that precision health becomes responsible only when biomarkers, AI outputs and patient-reported outcomes are embedded in correctable, goal-concordant and institutionally accountable learning systems. Full article

Breast cancer is the most common cancer in women, causing more than 600,000 deaths every year. The human microbiome is increasingly recognized as a key regulator of cancer initiation, progression, and therapeutic response. Postbiotics—defined as non-viable microbial cells and/or their structural components and metabolites that confer health benefits—are emerging as promising and safer alternatives to live probiotics in oncology. This review provides a comprehensive mechanistic overview of the potential role of postbiotics against cancer, with a specific focus on breast cancer. Preclinical evidence demonstrates that selected postbiotics exert dose- and time-dependent anticancer effects against multiple breast cancer subtypes by modulating key oncogenic pathways (such as PI3K/AKT and NF-κB) and inducing epigenetic regulation through histone deacetylase inhibition. Beyond direct effects on tumor cell proliferation and apoptosis, postbiotics influence the breast cancer microenvironment by reshaping cytokine networks, suppressing pro-metastatic inflammation, and enhancing antitumor immune responses through the activation of NK cells and T cells. We also provide emerging links between microbiome composition, estrobolome activity, and breast cancer subtype-specific biology. Despite these encouraging findings, the clinical translation of postbiotics in oncology remains limited. Currently, only one registered clinical trial investigates postbiotics in the oncology setting (melanoma), and no clinical trials have specifically evaluated postbiotics in breast cancer patients. This highlights a substantial translational gap between preclinical evidence and clinical application. Accordingly, well-designed, tumor-specific clinical trials are urgently needed to validate the safety, efficacy, and therapeutic potential of postbiotics as novel strategies in personalized breast cancer management. Full article